drugset / Trial / NCT00057278
Gabapentin in Fibromyalgia Trial (GIFT)
Phase 2/3
Completed
150 enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
Timeline
- Start
- 2003-03
- Primary completion
- —
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gabapentin | Unknown | 1800 mg | — |
| Subject | Gabapentin | Unknown | 2400 mg | — |